Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Charles Quesenberry and Laurel Habel.
Charles Quesenberry
Connection Strength
4.780
Laurel Habel
  1. HOXB13:IL17BR and molecular grade index and risk of breast cancer death among patients with lymph node-negative invasive disease. Breast Cancer Res. 2013 Mar 14; 15(2):R24.
    View in: PubMed
    Score: 0.453
  2. Mammographic density and risk of second breast cancer after ductal carcinoma in situ. Cancer Epidemiol Biomarkers Prev. 2010 Oct; 19(10):2488-95.
    View in: PubMed
    Score: 0.382
  3. Declining recurrence among ductal carcinoma in situ patients treated with breast-conserving surgery in the community setting. Breast Cancer Res. 2009; 11(6):R85.
    View in: PubMed
    Score: 0.360
  4. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res. 2006; 8(3):R25.
    View in: PubMed
    Score: 0.283
  5. Use of raloxifene among women with a history of breast cancer. Breast Cancer Res Treat. 2006 Mar; 96(2):123-9.
    View in: PubMed
    Score: 0.278
  6. A Cohort Study of Metformin and Colorectal Cancer Risk among Patients with Diabetes Mellitus. Cancer Epidemiol Biomarkers Prev. 2018 05; 27(5):525-530.
    View in: PubMed
    Score: 0.162
  7. Metformin use and lung cancer risk in patients with diabetes. Cancer Prev Res (Phila). 2015 Feb; 8(2):174-9.
    View in: PubMed
    Score: 0.129
  8. Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: a cohort from an integrated health care delivery system. J Clin Oncol. 2014 Jul 10; 32(20):2151-8.
    View in: PubMed
    Score: 0.123
  9. Cohort study of insulin glargine and risk of breast, prostate, and colorectal cancer among patients with diabetes. Diabetes Care. 2013 Dec; 36(12):3953-60.
    View in: PubMed
    Score: 0.118
  10. Risk factors for non-invasive and invasive local recurrence in patients with ductal carcinoma in situ. Breast Cancer Res Treat. 2013 Jun; 139(2):453-60.
    View in: PubMed
    Score: 0.114
  11. The epidemiology of herpes zoster in patients with newly diagnosed cancer. Cancer Epidemiol Biomarkers Prev. 2013 Jan; 22(1):82-90.
    View in: PubMed
    Score: 0.110
  12. Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care. 2011 Apr; 34(4):923-9.
    View in: PubMed
    Score: 0.099
  13. Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories. J Clin Oncol. 2010 Oct 01; 28(28):4300-6.
    View in: PubMed
    Score: 0.095
  14. Treatment of ductal carcinoma in situ among patients cared for in large integrated health plans. Am J Manag Care. 2010 May; 16(5):351-60.
    View in: PubMed
    Score: 0.093
  15. Active, but not passive cigarette smoking was inversely associated with mammographic density. Cancer Causes Control. 2010 Feb; 21(2):301-11.
    View in: PubMed
    Score: 0.091
  16. Relationship between clinical and pathologic features of ductal carcinoma in situ and patient age: an analysis of 657 patients. Am J Surg Pathol. 2009 Dec; 33(12):1802-8.
    View in: PubMed
    Score: 0.090
  17. Screening pharmaceuticals for possible carcinogenic effects: initial positive results for drugs not previously screened. Cancer Causes Control. 2009 Dec; 20(10):1821-35.
    View in: PubMed
    Score: 0.090
  18. Epidemiologic evaluation of pharmaceuticals with limited evidence of carcinogenicity. Int J Cancer. 2009 Nov 01; 125(9):2173-8.
    View in: PubMed
    Score: 0.090
  19. Thiazolidinedione therapy is not associated with increased colonic neoplasia risk in patients with diabetes mellitus. Gastroenterology. 2008 Dec; 135(6):1914-23, 1923.e1.
    View in: PubMed
    Score: 0.083
  20. Pharmaceuticals that cause mammary gland tumors in animals: findings in women. Breast Cancer Res Treat. 2009 Jul; 116(1):187-94.
    View in: PubMed
    Score: 0.082
  21. Erratum: Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361 859 recipients. Pharmacoepidemiol Drug Saf. 2008 Jul; 17(7):751.
    View in: PubMed
    Score: 0.082
  22. Glycemic status and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2008 Mar; 17(3):628-35.
    View in: PubMed
    Score: 0.080
  23. Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf. 2008 Jan; 17(1):27-36.
    View in: PubMed
    Score: 0.079
  24. Menstrual and reproductive factors in relation to mammographic density: the Study of Women's Health Across the Nation (SWAN). Breast Cancer Res Treat. 2008 Nov; 112(1):165-74.
    View in: PubMed
    Score: 0.079
  25. Methylphenidate use in children and risk of cancer at 18 sites: results of surveillance analyses. Pharmacoepidemiol Drug Saf. 2007 Dec; 16(12):1268-72.
    View in: PubMed
    Score: 0.079
  26. Medical therapy for diabetes is associated with increased use of lower endoscopy. Pharmacoepidemiol Drug Saf. 2007 Nov; 16(11):1195-202.
    View in: PubMed
    Score: 0.078
  27. Mammographic density in a multiethnic cohort. Menopause. 2007 Sep-Oct; 14(5):891-9.
    View in: PubMed
    Score: 0.077
  28. Clinical and pathologic features of ductal carcinoma in situ associated with the presence of flat epithelial atypia: an analysis of 543 patients. Mod Pathol. 2007 Nov; 20(11):1149-55.
    View in: PubMed
    Score: 0.077
  29. Antibiotics and risk of breast cancer: up to 9 years of follow-up of 2.1 million women. Cancer Epidemiol Biomarkers Prev. 2006 Nov; 15(11):2102-6.
    View in: PubMed
    Score: 0.073
  30. Examining the role of access to care: Racial/ethnic differences in receipt of resection for early-stage non-small cell lung cancer among integrated system members and non-members. Lung Cancer. 2018 Nov; 125:51-56.
    View in: PubMed
    Score: 0.041
  31. Exercise and Prognosis on the Basis of Clinicopathologic and Molecular Features in Early-Stage Breast Cancer: The LACE and Pathways Studies. Cancer Res. 2016 09 15; 76(18):5415-22.
    View in: PubMed
    Score: 0.036
  32. Exercise and Risk of Cardiovascular Events in Women With Nonmetastatic Breast Cancer. J Clin Oncol. 2016 08 10; 34(23):2743-9.
    View in: PubMed
    Score: 0.035
  33. Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes. JAMA. 2015 Jul 21; 314(3):265-77.
    View in: PubMed
    Score: 0.033
  34. Risk Prediction for Local Breast Cancer Recurrence Among Women with DCIS Treated in a Community Practice: A Nested, Case-Control Study. Ann Surg Oncol. 2015 Dec; 22 Suppl 3:S502-8.
    View in: PubMed
    Score: 0.033
  35. A large multiethnic genome-wide association study of prostate cancer identifies novel risk variants and substantial ethnic differences. Cancer Discov. 2015 Aug; 5(8):878-91.
    View in: PubMed
    Score: 0.033
  36. Breastfeeding, PAM50 tumor subtype, and breast cancer prognosis and survival. J Natl Cancer Inst. 2015 Jul; 107(7).
    View in: PubMed
    Score: 0.033
  37. Association of high obesity with PAM50 breast cancer intrinsic subtypes and gene expression. BMC Cancer. 2015 Apr 14; 15:278.
    View in: PubMed
    Score: 0.033
  38. Imputation of the rare HOXB13 G84E mutation and cancer risk in a large population-based cohort. PLoS Genet. 2015 Jan; 11(1):e1004930.
    View in: PubMed
    Score: 0.032
  39. Proteinuria testing among patients with diabetes mellitus is associated with bladder cancer diagnosis: potential for unmeasured confounding in studies of pioglitazone and bladder cancer. Pharmacoepidemiol Drug Saf. 2014 Jun; 23(6):636-45.
    View in: PubMed
    Score: 0.031
  40. Race and breast cancer survival by intrinsic subtype based on PAM50 gene expression. Breast Cancer Res Treat. 2014 Apr; 144(3):689-99.
    View in: PubMed
    Score: 0.030
  41. Intrinsic subtypes from PAM50 gene expression assay in a population-based breast cancer cohort: differences by age, race, and tumor characteristics. Cancer Epidemiol Biomarkers Prev. 2014 May; 23(5):714-24.
    View in: PubMed
    Score: 0.030
  42. Intrinsic subtypes from the PAM50 gene expression assay in a population-based breast cancer survivor cohort: prognostication of short- and long-term outcomes. Cancer Epidemiol Biomarkers Prev. 2014 May; 23(5):725-34.
    View in: PubMed
    Score: 0.030
  43. Ten-year risk of diagnostic mammograms and invasive breast procedures after breast-conserving surgery for DCIS. J Natl Cancer Inst. 2012 Apr 18; 104(8):614-21.
    View in: PubMed
    Score: 0.027
  44. A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. Lancet. 2012 Mar 03; 379(9818):823-32.
    View in: PubMed
    Score: 0.026
  45. Serial glycosylated hemoglobin levels and risk of colorectal neoplasia among patients with type 2 diabetes mellitus. Cancer Epidemiol Biomarkers Prev. 2010 Dec; 19(12):3027-36.
    View in: PubMed
    Score: 0.024
  46. Statin use and risk of colorectal cancer in a cohort of middle-aged men in the US: a prospective cohort study. Drugs. 2009 Jul 30; 69(11):1445-57.
    View in: PubMed
    Score: 0.022
  47. Adherence to long-term surveillance mammography among women with ductal carcinoma in situ treated with breast-conserving surgery. J Clin Oncol. 2009 Jul 01; 27(19):3211-6.
    View in: PubMed
    Score: 0.022
  48. Race, ethnicity, sex and temporal differences in Barrett's oesophagus diagnosis: a large community-based study, 1994-2006. Gut. 2009 Feb; 58(2):182-8.
    View in: PubMed
    Score: 0.021
  49. Helicobacter pylori and gastroesophageal reflux disease: a case-control study. Helicobacter. 2008 Oct; 13(5):352-60.
    View in: PubMed
    Score: 0.021
  50. Iron intake and body iron stores as risk factors for Barrett's esophagus: a community-based study. Am J Gastroenterol. 2008 Dec; 103(12):2997-3004.
    View in: PubMed
    Score: 0.021
  51. Hemochromatosis gene status as a risk factor for Barrett's esophagus. Dig Dis Sci. 2008 Dec; 53(12):3095-102.
    View in: PubMed
    Score: 0.020
  52. Re: Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst. 2008 Apr 16; 100(8):597-8; author reply 599.
    View in: PubMed
    Score: 0.020
  53. Statin use and risk of prostate cancer in the California Men's Health Study cohort. Cancer Epidemiol Biomarkers Prev. 2007 Nov; 16(11):2218-25.
    View in: PubMed
    Score: 0.020
  54. Helicobacter pylori infection and the risk of Barrett's oesophagus: a community-based study. Gut. 2008 Jun; 57(6):727-33.
    View in: PubMed
    Score: 0.019
  55. Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors. Breast Cancer Res Treat. 2008 Jun; 109(3):573-9.
    View in: PubMed
    Score: 0.019
  56. Abdominal obesity and body mass index as risk factors for Barrett's esophagus. Gastroenterology. 2007 Jul; 133(1):34-41; quiz 311.
    View in: PubMed
    Score: 0.019
  57. California Men's Health Study (CMHS): a multiethnic cohort in a managed care setting. BMC Public Health. 2006 Jun 30; 6:172.
    View in: PubMed
    Score: 0.018

© 2024 Kaiser Permanente